Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Publication | Closed Access

DOI

141

Citations

References

2019

Year

Hans‐Jürgen Stellbrink, José Ramón Arribas, Jeffrey L. Stephens, Helmut Albrecht, Paul E. Sax, Franco Maggiolo, Catherine Creticos, Claudia Martorell, Xuelian Wei, Rima Acosta,

The Lancet HIV

Week 96Antiviral Drug DevelopmentAntiviral TherapyVirologyPharmacotherapyHiv-1 InfectionTenofovir AlafenamideHivAntiviral DrugMedicineAntiviral Compound